Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Beneficio sostenido del tratamiento con seralutinib: un análisis post-hoc del estudio de extensión abierta TORREY

Thursday, July 10, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the sustained benefits of seralutinib treatment based on a post-hoc analysis of the open-label TORREY extension study. This analysis highlights the promising results associated with the drug, indicating its potential effectiveness in treating conditions like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings contribute to the growing body of evidence supporting seralutinib's use.
Price reaction · baseline $1.36 (2025-07-09 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sustained benefit observed with seralutinib treatment.
  • Post-hoc analysis indicates promising results.
  • Study contributes valuable data to ongoing research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Beneficio sostenido del tratamiento con seralutinib: un análisis post-hoc del estudio de extensión abierta TORREY
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib used for?

Seralutinib is used to treat conditions like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What did the TORREY study analyze?

The TORREY study conducted a post-hoc analysis to evaluate the sustained benefits of seralutinib treatment.

What are the results of the seralutinib study?

The study indicates promising results, showing sustained benefits from seralutinib treatment.

Is there ongoing research on seralutinib?

Yes, the findings contribute to ongoing research into the effectiveness of seralutinib.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib TORREY study PAH PH-ILD
Last updated: Jul 10, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →